GeoPharma to re-focus, terminates deal with AMERIGROUP

6 May 2007

USA-based firms GeoPharma AMERIGROUP New York have agreed to an amicable mutual termination of their pharmacy benefit management and services agreement in a manner that will allow each party to pursue its respective business interests.

Under the accord, GeoPharma previously managed AMERIGROUP's health care plan members and administrated the members' related pharmacy claims. The company has made a decision to concentrate its efforts on its core business, which involves the manufacturing, packaging and distribution of private label dietary and nutritional supplements, over-the-counter and generic drugs, as well as health and beauty products. The termination of the deal will become effective on May 15, unless extended by the parties for one or more 30-day periods as needed for the transition of services to another pharmacy vendor. This decision is not expected to have a material impact on GeoPharma's net profit.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight